Petrelintide
A long-acting amylin analog from Zealand Pharma being developed for obesity and overweight.
Also appears in: Hormone
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 6 trials · 4 PubMed results
Petrelintide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Petrelintide has 6 name-matched clinical trials (highest phase: Phase 2) and 4 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What petrelintide is
Petrelintide is a long-acting amylin analog from Zealand Pharma being developed for weight management in obesity and overweight.
Why it matters
It helps show how serious the amylin category has become. Petrelintide is not just another vendor-catalog peptide; it is part of a real clinical-development push toward alternatives and complements to GLP-1 therapy.
Regulatory context
Petrelintide is not FDA approved. It belongs in the investigational category.
Practical reading note
If GLP-1 drugs define the current obesity era, petrelintide belongs to the group of drugs trying to define what comes after “GLP-1 only.”